Tumor localization and biochemical response to cure in tumor-induced osteomalacia

被引:116
作者
Chong, William H. [1 ]
Andreopoulou, Panagiota [1 ,2 ]
Chen, Clara C. [3 ]
Reynolds, James [3 ]
Guthrie, Lori [1 ]
Kelly, Marilyn [1 ]
Gafni, Rachel I. [1 ]
Bhattacharyya, Nisan [1 ]
Boyce, Alison M. [1 ,4 ,5 ]
El-Maouche, Diala [1 ]
Crespo, Diana Ovejero [1 ]
Sherry, Richard [6 ]
Chang, Richard [3 ]
Wodajo, Felasfa M. [7 ]
Kletter, Gad B. [8 ]
Dwyer, Andrew [3 ]
Collins, Michael T. [1 ]
机构
[1] Natl Inst Dent & Craniofacial Res, Skeletal Clin Studies Unit, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA
[2] Montefiore Med Ctr, Einstein Coll Med, Dept Med, Div Endocrinol, Bronx, NY 10467 USA
[3] NIH, Hatfield Clin Res Ctr, Bethesda, MD 20892 USA
[4] Childrens Natl Med Ctr, Bone Hlth Program, Div Orthopaed & Sports Med, Washington, DC 20010 USA
[5] Childrens Natl Med Ctr, Div Endocrinol & Diabet, Washington, DC 20010 USA
[6] NCI, Surg Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[7] Virginia Hosp Ctr, Arlington, VA USA
[8] Swedish Med Ctr, Swedish Pediat Specialty Clin, Seattle, WA USA
关键词
FGF23; HYPOPHOSPHATEMIA; MINERAL METABOLISM; VITAMIN D; OSTEOMALACIA; OF-THE-LITERATURE; ONCOGENIC-OSTEOMALACIA; HYPOPHOSPHATEMIC OSTEOMALACIA; MESENCHYMAL TUMORS; SCINTIGRAPHY; MANAGEMENT; FGF23;
D O I
10.1002/jbmr.1881
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tumor-induced osteomalacia (TIO) is a rare disorder of phosphate wasting due to fibroblast growth factor-23 (FGF23)-secreting tumors that are often difficult to locate. We present a systematic approach to tumor localization and postoperative biochemical changes in 31 subjects with TIO. All had failed either initial localization, or relocalization (in case of recurrence or metastases) at outside institutions. Functional imaging with 111Indium-octreotide with single photon emission computed tomography (octreo-SPECT or SPECT/CT), and 18fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT) were performed, followed by anatomic imaging (CT, MRI). Selective venous sampling (VS) was performed when multiple suspicious lesions were identified or high surgical risk was a concern. Tumors were localized in 20 of 31 subjects (64.5%). Nineteen of 20 subjects underwent octreo-SPECT imaging, and 16 of 20 FDG-PET/CT imaging. Eighteen of 19 (95%) were positive on octreo-SPECT, and 14 of 16 (88%) on FDG-PET/CT. Twelve of 20 subjects underwent VS; 10 of 12 (83%) were positive. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were as follows: sensitivity=0.95, specificity=0.64, PPV=0.82, and NPV=0.88 for octreo-SPECT; sensitivity=0.88, specificity=0.36, PPV=0.62, and NPV=0.50 for FDG-PET/CT. Fifteen subjects had their tumor resected at our institution, and were disease-free at last follow-up. Serum phosphorus returned to normal in all subjects within 1 to 5 days. In 10 subjects who were followed for at least 7 days postoperatively, intact FGF23 (iFGF23) decreased to near undetectable within hours and returned to the normal range within 5 days. C-terminal FGF23 (cFGF23) decreased immediately but remained elevated, yielding a markedly elevated cFGF23/iFGF23 ratio. Serum 1,25-dihydroxyvitamin D3 (1,25D) rose and exceeded the normal range. In this systematic approach to tumor localization in TIO, octreo-SPECT was more sensitive and specific, but in many cases FDG-PET/CT was complementary. VS can discriminate between multiple suspicious lesions and increase certainty prior to surgery. Sustained elevations in cFGF23 and 1,25D were observed, suggesting novel regulation of FGF23 processing and 1,25D generation.
引用
收藏
页码:1386 / 1398
页数:13
相关论文
共 20 条
[1]   Selective Venous Catheterization for the Localization of Phosphaturic Mesenchymal Tumors [J].
Andreopoulou, Panagiota ;
Dumitrescu, Claudia E. ;
Kelly, Marilyn H. ;
Brillante, Beth A. ;
Peck, Carolee M. Cutler ;
Wodajo, Felasfa M. ;
Chang, Richard ;
Collins, Michael T. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (06) :1295-1302
[2]   Case 33-2011: A 56-Year-Old Man with Hypophosphatemia [J].
Bergwitz, Clemens ;
Collins, Michael T. ;
Kamath, Ravi S. ;
Rosenberg, Andrew E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (17) :1625-1635
[3]   Mechanism of FGF23 processing in fibrous dysplasia [J].
Bhattacharyya, Nisan ;
Wiench, Malgorzata ;
Dumitrescu, Claudia ;
Connolly, Brian M. ;
Bugge, Thomas H. ;
Patel, Himatkumar V. ;
Gafni, Rachel I. ;
Cherman, Natasha ;
Cho, Monique ;
Hager, Gordon L. ;
Collins, Michael T. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (05) :1132-1141
[4]   The Importance of Whole Body Imaging in Tumor-Induced Osteomalacia [J].
Chong, William H. ;
Yavuz, Sahzene ;
Patel, Shrita M. ;
Chen, Clara C. ;
Collins, Michael T. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (12) :3599-3600
[5]   Tumor-induced osteomalacia [J].
Chong, William H. ;
Molinolo, Alfredo A. ;
Chen, Clara C. ;
Collins, Michael T. .
ENDOCRINE-RELATED CANCER, 2011, 18 (03) :R53-R77
[6]  
de Beur SMJ, 2005, JAMA-J AM MED ASSOC, V294, P1260
[7]   Oncogenic osteomalacia: culprit tumour detection whole body magnetic resonance imaging [J].
Dissanayake, AM ;
Wilson, JL ;
Holdaway, IM ;
Reid, IR .
INTERNAL MEDICINE JOURNAL, 2003, 33 (12) :615-616
[8]   Tumor-Induced Osteomalacia [J].
Drezner M.K. .
Reviews in Endocrine and Metabolic Disorders, 2001, 2 (2) :175-186
[9]   Clinical Impact of Somatostatin Receptor Scintigraphy in the Management of Tumor-induced Osteomalacia [J].
Duet, Michele ;
Kerkeni, Samar ;
Sfar, Raja ;
Bazille, Cecile ;
Liote, Frederic ;
Orcel, Philippe .
CLINICAL NUCLEAR MEDICINE, 2008, 33 (11) :752-756
[10]  
Dupond Jean-Louis, 2005, Eur J Intern Med, V16, P445, DOI 10.1016/j.ejim.2005.07.003